Comparative cost efficiency across the European G5 countries of originators and a biosimilar erythropoiesis-stimulating agent to manage chemotherapy-induced anemia in patients with cancer

Therapeutic Advances in Medical Oncology

Volumn 4, Issue 3, 2012, Pages 95-105

  Aapro, Matti ^a   Cornes, Paul ^b   Sun, Diana ^c   Abraham, Ivo ^c  

^a CLINIQUE DE GENOLIER   (Switzerland)

^b BRISTOL HAEMATOLOGY AND ONCOLOGY CENTRE   (United Kingdom)

^c UNIVERSITY OF ARIZONA   (United States)

Author keywords

anemia; biosimilars; cost efficiency; cost savings; erythropoiesis stimulating agents; erythropoietin

Indexed keywords

NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ARTICLE; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED ANEMIA; COMPARATIVE STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG DOSE ESCALATION; FRANCE; GERMANY; HUMAN; ITALY; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SPAIN; UNITED KINGDOM;

EID: 84864487642     PISSN: 17588340     EISSN: 17588359     Source Type: Journal    
DOI: 10.1177/1758834012444499     Document Type: Article

References (31)

1. Aapro M. Cornes P. Abraham I. (2011) Comparative cost-efficiency across the European G 5 countries of various regimens of filgrastim, biosimilar filgrastim, and pegylated filgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia. J Oncol Pharm Pract 24 May [Epub ahead of print].
2. Aapro M.S. Link H. (2008) September 2007 update on EORTC guidelines and anaemia management with erythropoiesis-stimulating agents. Oncologist 13(Suppl. 3): 33–36.
3. Aapro M. Spivak J.L. (2009) Update on erythropoiesis-stimulating agents and clinical trials in oncology. Oncologist 14(Suppl. 1): 6–15.
4. Aapro M. van Erps J. MacDonald K. Soubeyran P. Muenzberg M. Turner M. et al. (2009) Managing cancer-related anaemia in congruence with the EORTC guidelines is an independent predictor of haemoglobin outcome: initial evidence from the RESPOND study. Eur J Cancer 45: 8–11.
5. Abraham I. Sun D. (2012) The cost of blood transfusion in Europe an estimate from six studies. Transfusion. DOI: 10.1111/j.1537-2995.2011.03532.x10.1111/j.1537-2995.2011.03532.x.
6. Auerbach M. Ballard H. Trout J.R. McIlwain M. Ackerman A. Bahrain H. et al. (2004) Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol 22: 1301–1307.
7. Auerbach M. Silberstein P.T. Webb R.T. Averyanove A. Ciuleanu T.E. Shao J. et al. (2010) Darbepoetin alfa 300 or 500 µg once every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. Am J Hematol 85: 655–663.
8. Bastit L. Vandebroek A. Altintas S. Gaede B. Pintér T. Suto T.S. et al. (2008) Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J Clin Oncol 26: 1611–1618.
9. Bokemeyer C. Aapro M.S. Courdi A. Foubert J. Link H. Osterborg A. et al. (2007) EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 43: 258–270.
10. Cornes P. Coiffier B. Zambrowski J.J. (2007) Erythropoietic therapy for the treatment of anemia in patients with cancer: a valuable clinical and economic option. Curr Med Res Opin 23: 357–368.
11. D'Almeida M.S. Jagger J. Duggan M. White M. Ellis C. Chin-Yee I.H. (2000) A comparison of biochemical and functional alterations of rat and human erythrocytes stored in CPDA-1 for 29 days: implications for animal models of transfusion. Transfus Med 10: 291–303.
12. Eurostat European Statistics (2011) Available at: http://epp.eurostat.ec.europa.eu/tgm/table.do?tab=table&language=en&pcode=tps00001&tableSelection=1&footnotes=yes&labeling=labels&plugin=1 (accessed 20 November 2011).
13. Glaspy J. Crawford J. Vansteenkiste J. Henry D. Rao S. Bowers P. et al. (2010) Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br J Cancer 102: 301–315.
14. Haag-Weber M. Vetter A. Thyroff-Friesinger U. (2009) Therapeutic equivalence, long-term efficacy and safety of HX 575 in the treatment of anemia in chronic renal failure patients receiving hemodialysis. Clin Nephrol 72: 380–390.
15. Hedenus M. Birgegård G. Näsman P. Ahlberg L. Karlsson T. Lauri B. et al. (2007) Addition of intravenous iron to epoetin β increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study. Leukemia 21: 627–632.
16. Jones M. Schenkel B. Just J. Fallowfield L. (2004) Epoetin alfa improves quality of life in patients with cancer: results of meta-analysis. Cancer 101: 1720–1732.
17. Kerkhofs L. Boschetti G. Lugini A. Stanculeanu D. Garcia Palomo A. (2012) Use of biosimilar epoetin to increase hemoglobin levels in patients with chemotherapy-induced anemia: real-life clinical practice. Future Oncol. DOI: 10.2217/FON.12.3910.2217/FON.12.39.
18. Kimel M. Leidy N.K. Mannix S. Dixon J. (2008) Does epoetin alfa improve health-related quality of life in chronically ill patients with anemia? Summary of trials of cancer, HIV/AIDS, and chronic kidney disease. Value Health 11: 57–75.
19. Koch C.G. Li L. Sessler D.I. Figueroa P. Hoeltge G.A. Mihaljevic T. Blackstone E.H. (2008) Duration of red-cell storage and complications after cardiac surgery. N Engl J Med 358: 1229–1239.
20. Littlewood T. Zambrowski J-J. Cornes P. (2006) Treating anaemia: deconstructing healthcare costs. Curr Med Res Opin 22(Suppl. 4): S23–S33.
21. Ludwig H. Aapro M. Bokemeyer C. Macdonald K. Soubeyran P. Turner M. et al. (2009) Treatment patterns and outcomes in the management of anaemia in cancer patients in Europe: findings from the anaemia Cancer Treatment (ACT) study. Eur J Cancer 45: 1603–1615.
22. Ludwig H. van Belle S. Barrett-Lee P. Birgegård G. Bokemeyer C. Gascón P. et al. (2004) The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 40: 2293–2306.
23. Macdougall I.C. Roger S.D. de Francisco A. Goldsmith D.J. Schellekens H. Ebbers H. et al. (2012) Antibody-mediated pure red cell aplasia in chronic kidney disease patients receiving erythropoiesis-stimulating agents: new insights. Kidney Int 81: 727–732.
24. Ode M. Roth K. Locatelli F. Hörl W. (2011) Switch from a broad range of erythropoiesis-stimulating agents to HX 575 (biosimilar epoetin alfa): a 6-month prospective multicenter study. Poster presentation at the XLVIII ERA-EDTA Congress, Prague, Czech Republic, June 2011.
25. Roger S.D. (2010) Biosimilars: current status and future directions. Expert Opin Biol Ther 10: 1011–1018.
26. Schrijvers D. de Samblanx H. Roila F. ; ESMO Guidelines Working Group (2010) Erythropoiesis-stimulating agents in the treatment of anaemia in cancer patients: ESMO Clinical Practice Guidelines for use. Ann Oncol 21(Suppl. 5): v244–v247.
27. Stramer S.L. Hollinger F.B. Katz L.M. Kleinman S. Metzel P.S. Gregory K.R. et al. (2009) Emerging infectious disease agents and their potential threat to transfusion safety. Transfusion 49(Suppl. 2): 1S–29S.
28. Szucs T.D. Blank P.R. Schwenkglenks M. Aapro M. (2011) Potential health economic impact of intravenous iron supplementation to erythropoiesis-stimulating agent treatment in patients with cancer- or chemotherapy-induced anaemia. Oncology 81: 45–49.
29. Tonelli M. Hemmelgarn B. Reiman T. Manns B. Reaume M.N. Lloyd A. et al. (2009) Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis. CMAJ 180: E62–E71.
30. Upile T. Jerjes W. Sandison A. Singh S. Rhys-Evans P. Sudhoff H. et al. (2008) The direct effects of stored blood products may worsen prognosis of cancer patients; shall we transfuse or not? An explanation of the adverse oncological consequences of blood product transfusion with a testable hypothesis driven experimental research protocol. Med Hypotheses 71: 498–502.
31. Weigang-Köhler K. Vetter A. Thyroff-Friesinger U. (2009) HX575, recombinant human epoetin alfa, for the treatment of chemotherapy-associated symptomatic anaemia in patients with solid tumours. Onkologie 32: 168–174.